Global Whole Genome Bisulfite Sequencing (WGBS) Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Whole Genome Bisulfite Sequencing (WGBS) Market Overview

The Whole Genome Bisulfite Sequencing (WGBS) Market was valued at USD 288.80 billion in 2025 and is projected to reach USD 1063.67 billion by 2033, growing at a CAGR of 17.70% from 2026 to 2033. The market is experiencing steady growth driven by the rising adoption of epigenetics research, increasing demand for precision medicine, and growing applications of DNA methylation analysis in oncology, developmental biology, and biomarker discovery. Advancements in next-generation sequencing technologies, declining sequencing costs, and expanding investments in genomics research are further accelerating the adoption of Whole Genome Bisulfite Sequencing (WGBS) solutions across academic, clinical, and pharmaceutical settings.

The increasing prevalence of cancer and genetic disorders globally, combined with growing emphasis on early disease detection and personalized therapeutics, is encouraging research institutions, biotechnology companies, and healthcare organizations to adopt advanced methylation sequencing technologies. Whole Genome Bisulfite Sequencing (WGBS) is increasingly replacing conventional targeted methylation analysis methods in many research applications by offering comprehensive, single-base resolution mapping of DNA methylation across the entire genome. In addition, advancements in automated library preparation, high-throughput sequencing platforms, cloud-based bioinformatics, and AI-enabled genomic analytics are improving workflow efficiency, reducing analysis time, and enabling large-scale epigenomic studies across both developed and emerging markets.

Key Market Trends & Insights

• North America dominated the Whole Genome Bisulfite Sequencing (WGBS) Market with the largest revenue share of 39.18% in 2025, supported by strong genomics research infrastructure, increasing investments in precision medicine, expanding cancer epigenetics studies, and the presence of leading biotechnology and sequencing technology companies across the U.S. and Canada.
• The early diagnosis of diseases segment dominated the market with a share of 38.42% in 2025 due to the increasing use of DNA methylation profiling for early detection of cancer, neurological disorders, and rare genetic diseases.
• Asia-Pacific is expected to be the fastest-growing region at a CAGR of 8.1% from 2026 to 2033, fueled by expanding genomics research programs, increasing government investments in precision medicine, rising biotechnology funding, and growing adoption of next-generation sequencing technologies across China, India, Japan, and South Korea.
• The Stem Cell Applications segment is projected to register the fastest CAGR of 7.8% from 2026 to 2033, reflecting the increasing use of WGBS technologies in stem cell differentiation studies, regenerative medicine research, and epigenetic biomarker discovery.
• The Pharmaceutical and Biotechnology Companies segment dominates the end user category with a 44.63% revenue share in 2025, supported by growing utilization of WGBS in oncology research, drug discovery, companion diagnostics, and personalized medicine development programs.
• The PCR Amplification segment accounts for a significant share of the market in 2025, owing to its essential role in generating sufficient bisulfite-converted DNA libraries for high-throughput sequencing and improving sequencing sensitivity in low-input genomic samples.
• The Early Diagnosis of Diseases application segment is anticipated to witness strong growth with a CAGR of 7.6% from 2026 to 2033, driven by rising adoption of epigenetic biomarkers for early cancer screening, neurodegenerative disease research, and non-invasive diagnostic testing applications.

Market Size & Forecast

• Global Market Value (2025): USD 288.80 Billion
• Expected Market Value (2033): USD 1063.67 Billion
• Forecast CAGR (2026–2033): 17.70%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia-Pacific

Report Scope and Whole Genome Bisulfite Sequencing (WGBS) Market Segmentation

Whole Genome Bisulfite Sequencing (WGBS) Market Trends

Trend: Rising Adoption of AI-Driven Epigenomics and Precision Medicine Research

Research institutions, pharmaceutical companies, and biotechnology firms are increasingly adopting advanced Whole Genome Bisulfite Sequencing (WGBS) technologies to study genome-wide DNA methylation patterns with single-base resolution accuracy. The integration of next-generation sequencing (NGS), artificial intelligence, and cloud-based bioinformatics platforms is enabling researchers to identify epigenetic biomarkers associated with cancer, neurological disorders, autoimmune diseases, and rare genetic conditions more efficiently than conventional methylation analysis methods. In addition, WGBS technologies are being widely utilized in stem cell biology, developmental biology, and regenerative medicine research to analyze epigenetic modifications influencing cellular differentiation and gene expression. The growing adoption of automated sequencing workflows, high-throughput sample processing systems, and AI-powered methylation analysis tools is significantly improving sequencing efficiency and data interpretation capabilities across clinical and academic research laboratories. For instance, several oncology studies have demonstrated that genome-wide methylation profiling can improve early-stage cancer detection sensitivity and support personalized treatment selection in precision oncology programs.

Whole Genome Bisulfite Sequencing (WGBS) Market Dynamics

Key Market Driver: Growing Demand for Precision Medicine and Epigenetic Biomarker Discovery

The rapid expansion of precision medicine, cancer genomics, and epigenetics-based drug discovery is significantly driving demand for Whole Genome Bisulfite Sequencing (WGBS) technologies globally. Pharmaceutical and biotechnology companies are increasingly utilizing WGBS platforms to identify disease-associated DNA methylation signatures, discover predictive biomarkers, and support the development of targeted therapeutics. WGBS enables comprehensive methylation mapping across the entire genome, allowing researchers to study gene regulation, tumor heterogeneity, and epigenetic alterations with high accuracy. Increasing investments in large-scale genomics initiatives and cancer epigenome research programs across North America and Europe are further accelerating market growth. In addition, rising use of WGBS in stem cell research, immunotherapy development, and rare disease analysis is expanding its application scope across both research and clinical environments. The growing availability of high-throughput sequencing systems and declining sequencing costs are also supporting wider adoption among academic institutes and contract research organizations.

Key Restraint/Challenge: High Cost and Computational Complexity of WGBS Workflows

A major challenge in the Whole Genome Bisulfite Sequencing (WGBS) Market is the high operational cost and computational complexity associated with large-scale methylation sequencing workflows. WGBS requires advanced sequencing platforms, specialized bisulfite conversion kits, high-performance computational infrastructure, and skilled bioinformatics professionals to process and interpret complex epigenomic datasets. The total cost of ownership includes library preparation, sequencing reagents, cloud storage, data analysis software, and ongoing system maintenance, making adoption difficult for smaller laboratories and resource-constrained research institutions. In addition, WGBS generates extremely large genomic datasets that require significant computational power and sophisticated algorithms for methylation alignment and analysis. For instance, comprehensive whole-genome methylation studies in oncology research may require terabytes of sequencing data processing, increasing storage and analysis costs substantially. These technical and financial barriers continue to limit widespread adoption, particularly in emerging markets and smaller academic facilities.

Key Market Opportunity: Integration of AI, Cloud Bioinformatics, and Multi-Omics Research Platforms

The integration of artificial intelligence, machine learning, and cloud-based bioinformatics platforms presents a significant growth opportunity for the Whole Genome Bisulfite Sequencing (WGBS) market. AI-enabled analytics tools can rapidly identify methylation signatures, classify disease patterns, and improve interpretation of complex epigenetic datasets while reducing analysis time and human error. The emergence of multi-omics research platforms integrating genomics, transcriptomics, proteomics, and methylomics data is creating strong demand for high-resolution WGBS technologies in translational medicine and biomarker discovery applications. In addition, cloud-connected sequencing analysis platforms are improving accessibility to advanced epigenomics workflows for academic institutions, CROs, and biotechnology startups across developing economies. Growing investments in population-scale genomics programs, cancer screening initiatives, and personalized medicine research across Asia-Pacific, Latin America, and the Middle East are expected to create substantial opportunities for next-generation WGBS solution providers over the coming years.

Whole Genome Bisulfite Sequencing (WGBS) Market Scope

The Whole Genome Bisulfite Sequencing (WGBS) market is segmented on the basis of product & service, application, and end user.

By Product & Service

On the basis of product & service, the Whole Genome Bisulfite Sequencing (WGBS) Market is segmented into DNA extraction, DNA fragmentation, DNA repair, adapter ligation, bisulfite treatment, and PCR amplification. The bisulfite treatment segment dominated the market with a share of 31.84% in 2025 due to its critical role in converting unmethylated cytosine into uracil, which is essential for accurate genome-wide DNA methylation analysis. Increasing adoption of epigenetics research in cancer biology, stem cell analysis, and precision medicine is significantly driving demand for high-efficiency bisulfite conversion kits and reagents. The segment benefits from continuous technological advancements that improve DNA recovery rates, sequencing accuracy, and workflow efficiency. In addition, rising investments in genomic medicine and large-scale methylation mapping projects are further supporting segment growth. Pharmaceutical companies and academic research institutes are increasingly utilizing advanced bisulfite treatment solutions for biomarker discovery and disease profiling studies. Growing use of automated library preparation systems and next-generation sequencing platforms is also accelerating adoption. The increasing prevalence of cancer and genetic disorders globally continues to expand the demand for accurate methylation sequencing workflows. Moreover, collaborations between biotechnology firms and sequencing technology providers are enhancing product innovation and accessibility. Rising government funding for epigenomics projects and personalized medicine initiatives is further strengthening the segment’s market position. The bisulfite treatment segment continues to remain the backbone of WGBS workflows due to its indispensable role in methylation analysis.

The PCR amplification segment is expected to witness the fastest CAGR of 9.1% from 2026 to 2033, driven by increasing demand for high-sensitivity DNA amplification techniques in low-input and degraded DNA samples. Advances in enzyme technologies and error-correction amplification methods are improving sequencing precision and reproducibility, making PCR amplification highly valuable for clinical and research applications. Growing adoption of WGBS in liquid biopsy testing, rare disease diagnostics, and oncology research is accelerating the need for efficient amplification solutions. In addition, increasing use of automated PCR systems and integrated sequencing workflows is improving laboratory productivity and scalability. The expansion of precision medicine initiatives and genomic testing programs across developed and emerging economies is also fueling segment growth. Pharmaceutical and biotechnology companies are investing heavily in high-throughput sequencing pipelines that rely on advanced PCR amplification technologies for accurate methylation profiling. Rising demand for epigenetic biomarkers in drug development and companion diagnostics is further supporting adoption. Technological innovations enabling reduced amplification bias and enhanced DNA yield are improving the effectiveness of WGBS workflows. Furthermore, increasing collaborations between sequencing companies and molecular diagnostics firms are driving commercialization of advanced amplification solutions. Expanding research activities in developmental biology, neurology, and cancer epigenetics are expected to sustain strong growth for the PCR amplification segment throughout the forecast period.

By Application

On the basis of application, the Whole Genome Bisulfite Sequencing (WGBS) Market is segmented into stem cell applications, developmental biology, early diagnosis of diseases, and forensic science. The early diagnosis of diseases segment dominated the market with a share of 38.42% in 2025 due to the increasing use of DNA methylation profiling for early detection of cancer, neurological disorders, and rare genetic diseases. WGBS technology enables comprehensive identification of epigenetic alterations associated with disease progression, supporting precision diagnostics and targeted therapies. Growing prevalence of cancer globally and increasing adoption of personalized medicine are significantly driving demand for advanced methylation sequencing technologies. Hospitals, research institutes, and biotechnology companies are increasingly integrating WGBS into clinical genomics and biomarker discovery programs. In addition, advancements in sequencing accuracy, bioinformatics platforms, and sample preparation technologies are enhancing diagnostic efficiency and scalability. Rising investments in liquid biopsy technologies and non-invasive diagnostic solutions are also contributing to market expansion. Governments and healthcare organizations are supporting genomic screening initiatives aimed at improving early disease detection and treatment outcomes. Increasing collaborations between pharmaceutical companies and genomic research institutes are accelerating epigenetic biomarker development. Furthermore, growing awareness regarding precision healthcare and preventive medicine is strengthening the adoption of WGBS in diagnostic applications. The segment continues to benefit from expanding applications of epigenetics in oncology, neurology, and autoimmune disease research.

The stem cell applications segment is projected to register the fastest CAGR of 9.4% from 2026 to 2033, driven by increasing research activities in regenerative medicine and cell therapy development. WGBS plays a critical role in analyzing epigenetic modifications during stem cell differentiation, reprogramming, and therapeutic development. Rising investments in stem cell research programs across North America, Europe, and Asia-Pacific are significantly boosting demand for comprehensive methylation sequencing technologies. Academic institutes and biotechnology companies are increasingly utilizing WGBS to understand cellular mechanisms and improve regenerative treatment outcomes. In addition, advancements in single-cell sequencing and high-throughput epigenomic analysis are enhancing the utility of WGBS in stem cell applications. Growing adoption of induced pluripotent stem cells (iPSCs) in disease modeling and drug discovery is further supporting market growth. Pharmaceutical companies are investing in epigenetic research to accelerate development of novel regenerative therapies and personalized medicine solutions. Increasing government support for stem cell banking and regenerative medicine initiatives is also creating growth opportunities. Furthermore, expanding applications of stem cell therapies in oncology, neurology, and tissue engineering are expected to drive long-term adoption of WGBS technologies. Continuous innovation in sequencing chemistry and data analytics platforms will further accelerate the growth of this segment during the forecast period.

By End User

On the basis of end user, the Whole Genome Bisulfite Sequencing (WGBS) Market is segmented into pharmaceutical and biotechnology companies, academic and government institutes, and contract research organizations. The pharmaceutical and biotechnology companies segment dominated the market with a share of 44.67% in 2025 due to increasing utilization of WGBS technologies in drug discovery, biomarker identification, and precision medicine development. These organizations are heavily investing in epigenetics research to improve therapeutic targeting and accelerate development of personalized treatment solutions. Rising demand for advanced genomic analysis tools in oncology, immunology, and rare disease research is driving strong adoption of WGBS platforms across pharmaceutical R&D operations. In addition, increasing collaborations between biotechnology firms and sequencing technology providers are supporting innovation in methylation sequencing workflows. The segment also benefits from rising investments in next-generation sequencing infrastructure and bioinformatics capabilities. Pharmaceutical companies are increasingly using WGBS to identify epigenetic biomarkers that support companion diagnostics and targeted therapies. Growing prevalence of chronic diseases and cancer worldwide is further accelerating demand for precision genomic technologies. Regulatory support for genomic medicine and biomarker-driven drug development is also reinforcing segment growth. Moreover, expansion of clinical genomics programs and translational research initiatives is improving adoption across commercial research settings. The pharmaceutical and biotechnology companies segment continues to lead the market due to its strong financial capabilities and increasing focus on advanced epigenomic research.

The contract research organizations (CROs) segment is anticipated to witness the fastest CAGR of 8.8% from 2026 to 2033, driven by rising outsourcing of genomic and epigenetic research activities by pharmaceutical and biotechnology companies. CROs are increasingly offering specialized WGBS services to support biomarker discovery, clinical trial analysis, and precision medicine development. Growing demand for cost-effective and scalable sequencing solutions is encouraging organizations to partner with CROs for advanced methylation analysis and bioinformatics support. In addition, increasing complexity of genomic research and rising need for high-throughput sequencing capabilities are accelerating outsourcing trends globally. CROs are investing in advanced sequencing platforms, automation technologies, and AI-driven analytics to improve operational efficiency and data accuracy. Expansion of clinical trials focused on oncology, rare diseases, and regenerative medicine is also fueling demand for WGBS-based epigenetic analysis services. Increasing collaborations between CROs and pharmaceutical firms are strengthening service capabilities and global market reach. Rising adoption of cloud-based genomic data management systems is further enhancing workflow scalability and remote collaboration. Furthermore, growing investments in precision medicine research and translational genomics are expected to create significant growth opportunities for CROs in the WGBS market. Continuous advancements in sequencing technologies and bioinformatics solutions will continue to support rapid expansion of this segment over the forecast period.

Whole Genome Bisulfite Sequencing (WGBS) Market Regional Analysis

North America dominated the Whole Genome Bisulfite Sequencing (WGBS) market and accounted for the largest revenue share of 39.18% in 2025, supported by strong genomics research infrastructure, increasing investments in precision medicine, expanding cancer epigenetics studies, and the presence of leading biotechnology and sequencing technology companies across the U.S. and Canada. The region also benefits from high adoption of next-generation sequencing (NGS) platforms, growing funding for large-scale genomic mapping projects, and increasing utilization of WGBS in oncology, rare disease research, and biomarker discovery applications. Rising collaborations between pharmaceutical companies, academic institutes, and genomic research organizations are further accelerating market growth. In addition, increasing demand for personalized medicine and methylation-based diagnostics continues to strengthen North America’s leadership position in the global market.

U.S. Whole Genome Bisulfite Sequencing (WGBS) Market Insight

The U.S. Whole Genome Bisulfite Sequencing (WGBS) market is witnessing strong growth due to rising investments in epigenetics research, precision medicine initiatives, and cancer genomics programs. The country’s advanced biotechnology ecosystem, along with the strong presence of leading sequencing platform providers and pharmaceutical companies, is driving widespread adoption of WGBS technologies across clinical and research applications. Increasing use of methylation sequencing in oncology diagnostics, biomarker discovery, and drug development is significantly boosting market demand. In addition, growing government support through programs funded by the National Institutes of Health (NIH) and expanding adoption of AI-powered genomic analytics platforms are accelerating technological advancements in the U.S. market.

Europe Whole Genome Bisulfite Sequencing (WGBS) Market Insight

The Europe Whole Genome Bisulfite Sequencing (WGBS) market remains a major contributor to global revenue, driven by increasing investments in genomic medicine, strong government support for life sciences research, and growing adoption of advanced sequencing technologies. Countries across the region are actively supporting epigenetics and cancer genomics research through national precision medicine programs and collaborative research initiatives. Increasing utilization of WGBS in developmental biology, stem cell research, and disease diagnostics is supporting market expansion throughout Europe. Furthermore, the presence of advanced healthcare infrastructure, highly skilled researchers, and expanding clinical genomics projects is strengthening regional adoption of WGBS technologies.

U.K. Whole Genome Bisulfite Sequencing (WGBS) Market Insight

The U.K. Whole Genome Bisulfite Sequencing (WGBS) market is experiencing steady growth, supported by rising investments in genomic sequencing initiatives, cancer epigenetics studies, and precision healthcare programs. The country’s strong academic research environment and government-backed genomics projects are accelerating the adoption of advanced methylation sequencing technologies. Increasing collaborations between biotechnology firms, research institutes, and healthcare organizations are driving innovation in epigenetic biomarker discovery and personalized medicine applications. Moreover, growing integration of bioinformatics, cloud computing, and AI-driven genomic analytics platforms is improving sequencing efficiency and expanding the application scope of WGBS across the U.K.

Germany Whole Genome Bisulfite Sequencing (WGBS) Market Insight

The Germany Whole Genome Bisulfite Sequencing (WGBS) market is expanding steadily due to the country’s advanced biotechnology sector, strong pharmaceutical industry presence, and increasing investments in genomic and epigenetic research. Research institutes, healthcare organizations, and biotechnology companies are increasingly utilizing WGBS technologies for cancer diagnostics, stem cell analysis, and translational medicine applications. Continuous advancements in next-generation sequencing platforms, automation technologies, and genomic data analytics are improving sequencing accuracy and laboratory efficiency. In addition, increasing government focus on precision medicine and biomedical innovation is further supporting market growth across Germany.

Asia-Pacific Whole Genome Bisulfite Sequencing (WGBS) Market Insight

The Asia-Pacific Whole Genome Bisulfite Sequencing (WGBS) market is expected to witness rapid growth at a CAGR of 8.1% from 2026 to 2033, driven by expanding genomics research programs, increasing government investments in precision medicine, rising biotechnology funding, and growing adoption of next-generation sequencing technologies across China, India, Japan, and South Korea. The region is witnessing increasing demand for advanced genomic analysis tools in oncology research, rare disease diagnostics, and regenerative medicine applications. Expanding healthcare infrastructure, rising biotechnology startup activity, and growing collaborations with global sequencing technology providers are supporting regional market expansion. Furthermore, increasing awareness regarding personalized medicine and precision diagnostics is accelerating adoption of WGBS technologies across both clinical and academic sectors.

Japan Whole Genome Bisulfite Sequencing (WGBS) Market Insight

The Japan Whole Genome Bisulfite Sequencing (WGBS) market is witnessing consistent growth due to increasing investments in precision genomics, cancer research, and advanced molecular diagnostics. Academic institutes, pharmaceutical companies, and biotechnology organizations are increasingly adopting WGBS technologies for methylation profiling, biomarker discovery, and stem cell research applications. The country’s strong focus on healthcare innovation, regenerative medicine, and genomic medicine initiatives is significantly contributing to market growth. Moreover, advancements in sequencing automation, AI-based genomic interpretation tools, and bioinformatics infrastructure are further improving research efficiency and supporting wider adoption across Japan.

China Whole Genome Bisulfite Sequencing (WGBS) Market Insight

The China Whole Genome Bisulfite Sequencing (WGBS) market is growing rapidly, driven by increasing investments in biotechnology research, expanding precision medicine initiatives, and rising adoption of next-generation sequencing technologies. Government-backed genomics programs, growing cancer research activities, and expanding clinical sequencing capabilities are significantly boosting market demand. Chinese biotechnology companies and academic institutions are increasingly utilizing WGBS technologies for epigenetic analysis, disease diagnostics, and pharmaceutical research applications. In addition, rising healthcare expenditure, expanding genomic databases, and rapid advancements in AI-enabled bioinformatics platforms are positioning China as one of the fastest-growing markets for Whole Genome Bisulfite Sequencing (WGBS) globally.

Whole Genome Bisulfite Sequencing (WGBS) Market Share

The Whole Genome Bisulfite Sequencing (WGBS) industry is primarily led by well-established companies, including:

• Illumina, Inc. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• QIAGEN N.V. (Netherlands)
• Pacific Biosciences of California, Inc. (U.S.)
• Oxford Nanopore Technologies plc (U.K.)
• Agilent Technologies, Inc. (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Merck KGaA (Germany)
• PerkinElmer Inc. (U.S.)
• Zymo Research Corporation (U.S.)
• New England Biolabs, Inc. (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• Takara Bio Inc. (Japan)
• Promega Corporation (U.S.)
• BGI Genomics Co., Ltd. (China)
• Eurofins Scientific (Luxembourg)
• Integrated DNA Technologies, Inc. (U.S.)
• Revvity, Inc. (U.S.)
• Novogene Co., Ltd. (China)
• Azenta Life Sciences (U.S.)
• SeqMatic LLC (U.S.)
• Basepair Inc. (U.S.)
• CD Genomics (U.S.)
• Active Motif, Inc. (U.S.)
• Norgen Biotek Corp. (Canada)
• Partek Incorporated (U.S.)
• Diagenode SA (Belgium)
• Creative Biogene (U.S.)
• GENEWIZ, Inc. (U.S.)
• Macrogen, Inc. (South Korea)

Latest Developments in Whole Genome Bisulfite Sequencing (WGBS) Market

• In February 2021, Illumina, Inc. highlighted advancements in Whole Genome Bisulfite Sequencing (WGBS) workflows through expanded support for high-throughput DNA methylation sequencing applications on its next-generation sequencing platforms. The company emphasized the growing adoption of WGBS in cancer epigenetics, biomarker discovery, and precision medicine research, strengthening its position in genome-wide methylation analysis solutions
• In September 2022, Illumina, Inc. announced that Whole Genome Bisulfite Sequencing (WGBS) Zymo-Seq data became available on the Illumina BaseSpace Sequence Hub platform. The integration enabled researchers to streamline methylation sequencing analysis workflows using cloud-based bioinformatics tools and advanced sequencing pipelines, improving accessibility and efficiency for epigenetics studies
• In June 2023, Illumina, Inc. announced that BaseSpace Sequence Hub added support for Whole Genome Bisulfite Sequencing (WGBS) data generated using the Zymo-Seq Library Kit on the NovaSeq X Series platform. This development improved scalability and throughput for genome-wide methylation analysis, supporting large-scale epigenomics and precision medicine research applications
• In August 2023, Zymo Research Corporation expanded its portfolio of methylation sequencing solutions with advancements in Zymo-Seq WGBS library preparation technologies designed for low-input DNA samples and high-throughput sequencing applications. The development supported increasing demand for accurate epigenetic profiling in oncology, stem cell, and developmental biology research
• In March 2024, Illumina, Inc. continued expanding adoption of WGBS technologies by promoting integrated methylation sequencing workflows combining NovaSeq X Series systems, DRAGEN bioinformatics, and advanced bisulfite sequencing applications. The initiative aimed to improve sequencing accuracy, reduce turnaround time, and accelerate epigenomics research in clinical and pharmaceutical applications
• In October 2024, Illumina, Inc. emphasized the growing importance of tagmentation-based whole genome bisulfite sequencing (T-WGBS) technologies for low-input and single-cell methylation analysis. The company highlighted the advantages of simplified workflows, reduced DNA loss, and improved sequencing efficiency for advanced epigenetics research and precision oncology applications
• In January 2025, Illumina, Inc. continued strengthening its methylation sequencing ecosystem by enhancing compatibility between WGBS workflows, AI-enabled genomic analytics, and cloud-based sequencing data platforms. The development supported increasing global demand for scalable genome-wide methylation analysis in translational research, biomarker discovery, and personalized medicine initiatives

SKU-55716